Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9ULT0
UPID:
TTC7A_HUMAN
Alternative names:
-
Alternative UPACC:
Q9ULT0; Q2T9J9; Q6PIX4; Q8ND67; Q9BUS3
Background:
Tetratricopeptide repeat protein 7A plays a pivotal role in cellular processes by ensuring the localization of phosphatidylinositol 4-kinase to the plasma membrane. This action is crucial for the synthesis of phosphatidylinositol 4-phosphate, a key lipid signaling molecule.
Therapeutic significance:
The protein's involvement in gastrointestinal defects and immunodeficiency syndrome 1 highlights its potential as a target for therapeutic intervention. Understanding the role of Tetratricopeptide repeat protein 7A could open doors to potential therapeutic strategies.